Clinical trials: Gene Mutations
NON-SMALL-CELL LUNG CANCER
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.
- Trial name
- NCT00831454
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Armando Santoro, MD
Lung Cancer, NSCLC
FGFR Inhibitor in FGFR Dysregulated Cancer
In the FIND trial, Non Small Cell Lung Carcinoma (NSCLC) patients with Fibroblast Growth Factor Receptor (FGFR) genetic alteration will be treated with the selective FGFR1-4 inhibitor erdafitinib.
- Conditions
- Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer
- Trial name
- FIND (NCT03827850)
- Testing
- ERDAFITINIB
- Where
- 11 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Lung Cancer Group Cologne
DMD, Duchenne Muscular Dystrophy
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
- Conditions
- DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44
- Trial name
- EXPLORE44OLE (NCT06244082)
- Testing
- AOC 1044
- Where
- 10 sites in United States
- Volunteers
- 39 people
- Sponsor
- Avidity Biosciences, Inc.
Acute Myeloid Leukemia
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3…
- Trial name
- NCT04293562
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection
- Where
- 206 sites in United States, Australia and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia With Gene Mutations
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
The goal of this clinical trial is to learn if the combination of oral decitabine plus ivosidenib works to treat naïve adult patients with acute myeloid leukemia (AML) with IDH1 R132 mutation older than 60 years old or those who…
- Trial name
- DECISIVO (NCT07507760)
- Testing
- Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Ivosidenib Oral Tablet, Hydroxyurea
- Where
- 20 sites in Portugal, Spain
- Volunteers
- 50 people
- Sponsor
- PETHEMA Foundation
Non-small Cell Lung Cancer
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
The purpose of this research study is to learn if adding hydroxychloroquine (HCQ) to erlotinib helps treat non-small cell lung cancer (NSCLC).
- Trial name
- NCT00977470
- Testing
- Erlotinib, Hydroxychloroquine
- Where
- 4 sites in United States
- Volunteers
- 76 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Breast Cancer Stage IV
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations.
- Conditions
- Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma
- Trial name
- NCT05054374
- Testing
- Mirdametinib, Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
To Determine the Prevalence, Penetrance of BRCA1 and BRCA2 Mutations in Romanian Womens With Breast or Ovarian Cancer
BRCA1 and BRCA2 Mutation in Romanian Population: a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival
Primary objective To determine BRCA1 and BRCA2 variants in 250 Romanian women with breast/ovarian cancer selected for likeliness to harbor germline mutations in these genes by specific criteria for high-risk status including age…
- Trial name
- NCT02317120
- Testing
- NGS BRCA 1 and BRCA 2 full sequencing, Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2
- Where
- Romania
- Volunteers
- 250 people
- Sponsor
- Alexandru Eniu
Uterine Cancer
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
This is an open-label treatment program following basic prescribing information for patients with recurrent UPSC (Uterine Papillary Serous Carcinoma) to provide access to everolimus and limited treatment alternatives.
- Trial name
- NCT03285802
- Testing
- Letrozole, Everolimus
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Greater Baltimore Medical Center
Waldenstrom's Disease
Detection of Recurrent Mutations in Waldenström's Disease
Waldenström's disease (WM) is a rare, low-grade lymphoid hematopathy, accounting for 1 to 2% of malignant hematopathies and mainly affecting the elderly.
- Trial name
- DigiWAL (NCT03952052)
- Testing
- Determination of mutation
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Henri Becquerel
Breast Cancer, Ductal Carcinoma
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia
- Trial name
- BabyTEARS (NCT07499999)
- Testing
- Exemestane, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
Therapy Related Myelodysplastic Syndrome and Therapy Related Acute Myeloid Leukemia
SRSF2 Gene Mutation in Patients With t-MDS/AML
To detect SRSF2 gene mutation by polymerase chain reaction (PCR) in the two types of t-MDS/AML which recognized in the WHO classification.
- Trial name
- NCT03894852
- Testing
- PCR and cytogenetics
- Where
- 2 sites in Egypt
- Volunteers
- 139 people
- Sponsor
- Zeinab Albadry Mohammed Zahran
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
The main purpose of this study is to evaluate the safety and efficacy of Apatinib in combination with Gefitinib as compared to placebo in combination with Gefitinib in participants with stage ⅢB-IV Non-squamous non-small-cell…
- Trial name
- NCT02824458
- Testing
- Apatinib, Gefitinib
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Sensorineural Hearing Loss, Hearing Disorder
Genetic Analysis of Hereditary Disorders of Hearing and Balance
This study will try to identify the genetic causes of hereditary hearing loss or balance disorders. People with a hearing or balance disorder that affects more than one family member may be eligible for this study.
- Conditions
- Sensorineural Hearing Loss, Hearing Disorder, Vestibular Disease
- Trial name
- NCT00023049
- Where
- 2 sites in United States, Nigeria
- Volunteers
- 335 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Gastric Cancer
Peritoneal Lavage for Early Detecting Gene Mutation of Peritoneal Metastasis of Gastric Cancer
Our study aims to improve sensitivity and accuracy of detecting abdominal free cancer cells in patients with gastric cancer.
- Trial name
- NCT03314649
- Testing
- Observational study
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
This phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT04493138
- Testing
- Azacitidine, Quizartinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
This phase I/II trial tests the safety, side effects, best dose and how well giving daraxonrasib works for the treatment of pediatric patients with solid tumors with RAS mutations that has come back after a period of improvement…
- Conditions
- Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma, Recurrent Childhood Rhabdomyosarcoma, Refractory Childhood Malignant Solid Neoplasm
- Trial name
- NCT07819838
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Volunteers
- 77 people
- Sponsor
- Children's Oncology Group
Wilms Tumor, Rhabdoid Tumor
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher…
- Conditions
- Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST
- Trial name
- NCT05985161
- Testing
- Selinexor
- Where
- 16 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care, which aims to understand whether the combination…
- Trial name
- NCT06276283
- Testing
- DZD9008 plus Bevacizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Dizal Pharmaceuticals
Advanced Malignant Neoplasm, ALK Fusion Protein Expression
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1 gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other places in the body.
- Conditions
- Advanced Malignant Neoplasm, ALK Fusion Protein Expression, ALK Gene Amplification, ALK Gene Mutation
- Trial name
- NCT03868423
- Testing
- Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Sameek Roychowdhury
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.